Result: Risk Minimisation Materials for medicines starting with the letter C

Capexion

Generics UK T/A Mylan

Patient Card for Tacrolimus

Patient card for Tacrolimus

Caprelsa

Genzyme Therapeutics

Caprelsa ( Vandetanib) – Patient Card - Risk Minimisation Information for Patients

This medicine is subject to additional monitoring. This will allow quick identication of new safety information. You can help by reporting any side effects you may get. In the UK see www.mhra.gov.uk/yellowcard for how to report side effects

Caprelsa (Vandetanib) - Patient Guide - Risk Minimisation Information for Patients

The guide should be provided to patients prior to treatment by the prescribing physician and includes a description of the risks of treatment, guidance on what to do in the event of risks occurring including your doctors contact details and an overview of treatment monitoring

Caprelsa (Vandetanib) -Healthcare Professional Letter

For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

For Healthcare Professionals

Cellcept

Roche Products Limited

CellCept (Mycophenolate mofetil) Guide for Healthcare Providers – Risk of teratogenicity

This material is provided by Roche Products Ltd and forms part of the licence requirement. Please ensure that you are familiar with this material as it contains important safety information

For Healthcare Professionals

Mycophenolate mofetil (CellCept): risks of miscarriage and birth defects – Patient guide

This material is provided by Roche Products Ltd as a licence requirement. Please ensure that you are familiar with this material as it contains important safety information.

Cerdelga

Genzyme Therapeutics

CERDELGA (eliglustat) Patient Alert card

For hard copies please contact our medical information department at 0845 372 7101 or email [email protected] .

Healthcare Professional Letter for Cerdelga® (eliglustat)

For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

For Healthcare Professionals

Prescriber Guide for CERDELGA (eliglustat)

For hard copies please contact our medical information department at 0845 372 7101 or email [email protected] .

For Healthcare Professionals

Cerezyme

Genzyme Therapeutics

Cerezyme (imiglucerase) - Home Infusion HCP Manual - Risk Minimisation Information for Healthcare Professionals

The objective of this document is to provide guidance to healthcare professionals for the management of patients receiving Cerezyme (imiglucerase) at home.

For Healthcare Professionals

Cerezyme (imiglucerase) - Home Infusion Patient Manual - Risk Minimisation Information for Patients

The objective of this document is to provide patients with guidance on how to receive Cerezyme (imiglucerase) at home. It is the responsibility of the treating physician to supply this material to patients only if the treating physician decides that the patient is eligible for home infusion treatment.

Cilest

Janssen-Cilag Ltd

Annex 2 Checklist for Prescribers

Checklist for prescribers to guide them on discussion with patients on risk factors associated with Combined hormonal contracpetives and thromboembolism

For Healthcare Professionals

Annex 3 Important Information for Women

Document summarises important risk factors of a blood clot and advises on action to be taken if certain symptoms are experienced

Annex 4 leaflet for women

Leaflet with information on combined oral contraception to be given to patient by the physician

Cimzia

UCB Pharma Limited

Cimzia Patient Alert card

This alert card contains important safety information that patients need to be aware of before they are given CIMZIA and during treatment with CIMZIA.

Cimzia Prescriber Guide

Educational Material

For Healthcare Professionals

Cinryze

Shire Pharmaceuticals Limited

Cinryze - Risk Management Plan Letter

Letter sent to HCPs informing them of the updated educational materials and website for the reconstitution and administraiton of Cinryze

Cinryze Patient Diary

This Patient Diary is intended for patients to use to record the date, lot numbers, and reason for injection each time they inject Cinryze (C1 esterase inhibitor [human]) so that they can share this information with their treating physician at their next visit.

Cinryze Reconstitution and Administration Instructions for Healthcare Professionals

This Healthcare Professional Guide provides instruction on the procedures for the reconstitution and administration of Cinryze (C1 inhibitor [human]).

For Healthcare Professionals

Instructions for Patients and Caregivers on the Preparation and Administration of Cinryze

This Guide is intended for Patients and Caregivers to provide instruction on the preparation and administration of Cinryze

Cleosensa

Accord-UK Ltd

Clexane

SANOFI

Clexane (enoxaparin sodium) - Professional letter HCP

Direct Healthcare Professional Communication, Clexane (enoxaparin sodium): Updates to strength expression, dose regimens in DVT/PE, use in patients with severe renal impairment For hard copies please contact our medical information department at 0845 372 7101 or email [email protected] .

For Healthcare Professionals

Concerta

Janssen-Cilag Ltd

Physician's guide to prescribing website

Website to host materials for physicians to support appropriate prescribing of methylphenidate

For Healthcare Professionals

Cubicin

Merck Sharp & Dohme Limited

Cubicin (daptomycin): Important safety information to minimise the risk of myotoxicity and dysregulation of in vivo coagulation- Dosage Card for Physicians

Under the Cubicin Marketing Authorisation, MSD are required to ensure that all HCPs likely to treat patients with daptomycin are provided with risk minimisation materials. This document contains key information to help minimize the risks of myotoxicity and dysregulation of in vivo coagulation. It also provides dosage recommendations and calculates the dose of daptomycin 50 mg/ml solution that is required from the weight of the patient. The licensed indications have been extended to include paediatric patients with S. aureus bacteraemia associated with cSSTI aged from 1 to 17 years of age. The document has been updated to include information on use in this population. If you require further information and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call MSD Medical Information Services on 01992 467272.

For Healthcare Professionals

Cubicin (daptomycin): Important safety information to minimise the risk of reduced susceptibility of S.aureus to daptomycin- The Laboratory Susceptibility Testing Leaflet

As part of the terms of the Marketing Authorisation for Cubicin, MSD are required to ensure that all Healthcare Professionals who are likely to treat patients with daptomycin are provided with risk minimisation materials. This document contains key information to help minimise the risk of reduced susceptibility of S.aureus to daptomycin. It also provides a detailed explanation of the susceptibility testing issues, including the need for calcium in the testing medium. The leaflet has been updated as follows: •Deletion of the reason why the BBL™ Mueller-Hinton test method is recommended in the E test section •Throughout the text, the range fort the Ca2+ concentration has also been displayed in ‘mmol/L’ •References updated If you require further information about daptomycin and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call MSD Medical Information Services on 01992 467272.

For Healthcare Professionals